Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + chemoradiotherapy + CAPOX as neoadjuvant therapy for locally advanced rectal adenocarcinoma (real-world study)
ChiCTR2200058590Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in rectal adenocarcinoma, sponsored by Henan Cancer Hospital. Primary endpoint: Pathological complete remission rate. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2200058590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058590.